Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma
Titel:
Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma
Auteur:
Kumar, Anita Casulo, Carla Yahalom, Joachim Schöder, Heiko Barr, Paul M. Caron, Philip Chiu, April Constine, Louis S. Drullinsky, Pamela Friedberg, Jonathan W. Gerecitano, John F. Hamilton, Audrey Hamlin, Paul A. Horwitz, Steven M. Jacob, Alexandra G. Matasar, Matthew J. McArthur, Gianna N. McCall, Susan J. Moskowitz, Alison J. Noy, Ariela Palomba, Maria L. Portlock, Carol S. Straus, David J. VanderEls, Nicholas Verwys, Stephanie L. Yang, Joanna Younes, Anas Zelenetz, Andrew D. Zhang, Zhigang Moskowitz, Craig H.